165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
| Autor: | Bartsch, R., Berghoff, A.S., Furtner, J., Marhold, M., Bergen, E.S., Roider-Schur, S., Starzer, A.M., Forstner, H., Rottenmanner, B., Dieckmann, K., Bago-Horvath, Z.A., Widhalm, G., Ilhan-Mutlu, A., Minichsdorfer, C., Fuereder, T., Singer, C.F., Weltermann, A., Puhr, R., Preusser, M. |
|---|---|
| Zdroj: | In Annals of Oncology May 2022 33 Supplement 3:S198-S198 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|